亨迪药业
(301211)
| 流通市值：43.89亿 | | | 总市值：43.89亿 |
| 流通股本：4.18亿 | | | 总股本：4.18亿 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 354,425,267.77 | 247,515,604.46 | 120,164,148.88 | 453,306,981.13 |
| 营业收入 | 354,425,267.77 | 247,515,604.46 | 120,164,148.88 | 453,306,981.13 |
| 二、营业总成本 | 343,756,681.94 | 238,669,614.7 | 119,112,800.57 | 439,869,142.57 |
| 营业成本 | 272,192,779.07 | 189,315,178.56 | 95,017,906.1 | 353,104,019.75 |
| 税金及附加 | 4,605,716.75 | 3,356,911.91 | 1,510,521.95 | 5,953,401.61 |
| 销售费用 | 14,269,896.08 | 10,481,234.88 | 5,102,851.18 | 20,636,163.31 |
| 管理费用 | 35,736,912.78 | 24,100,298.46 | 11,489,985.27 | 44,878,424.15 |
| 研发费用 | 18,944,622.99 | 12,671,265.37 | 5,497,981.82 | 25,180,041.91 |
| 财务费用 | -1,993,245.73 | -1,255,274.48 | 493,554.25 | -9,882,908.16 |
| 其中:利息费用 | 72,236.41 | 51,925.23 | 27,991.23 | 179,046.7 |
| 其中:利息收入 | 6,783,181.35 | 4,589,686.59 | 1,278,883.69 | 11,942,657.96 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 22,461,833.33 | 14,892,277.77 | 7,405,000 | 12,969,750.06 |
| 加:投资收益 | - | - | - | 16,165,741.61 |
| 资产处置收益 | -3,001.67 | -4,590.71 | - | 11,870.67 |
| 资产减值损失(新) | - | - | - | -4,346,634.5 |
| 信用减值损失(新) | 466,543.18 | 319,065.88 | -372,326.79 | -234,050.9 |
| 其他收益 | 9,356,150.44 | 9,347,037.22 | 2,166,410.71 | 3,851,104.29 |
| 四、营业利润 | 42,950,111.11 | 33,399,779.92 | 10,250,432.23 | 41,855,619.79 |
| 加:营业外收入 | 2,500 | - | - | 470,931.84 |
| 减:营业外支出 | 127,555.38 | 6,850.71 | 419.63 | 1,065,613.63 |
| 五、利润总额 | 42,825,055.73 | 33,392,929.21 | 10,250,012.6 | 41,260,938 |
| 减:所得税费用 | 3,167,280.43 | 3,256,867.33 | 1,031,948.95 | 6,350,339.21 |
| 六、净利润 | 39,657,775.3 | 30,136,061.88 | 9,218,063.65 | 34,910,598.79 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 39,657,775.3 | 30,136,061.88 | 9,218,063.65 | 34,910,598.79 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 39,657,775.3 | 30,136,061.88 | 9,218,063.65 | 34,910,598.79 |
| 扣除非经常损益后的净利润 | 14,377,439.53 | 11,198,858.51 | 2,518,836.6 | 7,883,456.48 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.09 | 0.07 | 0.02 | 0.08 |
| (二)稀释每股收益 | 0.09 | 0.07 | 0.02 | 0.08 |
| 八、其他综合收益 | - | - | - | 628,950.39 |
| 归属于母公司股东的其他综合收益 | - | - | - | 628,950.39 |
| 九、综合收益总额 | 39,657,775.3 | 30,136,061.88 | 9,218,063.65 | 35,539,549.18 |
| 归属于母公司股东的综合收益总额 | 39,657,775.3 | 30,136,061.88 | 9,218,063.65 | 35,539,549.18 |
| 公告日期 | 2026-10-27 | 2026-08-25 | 2026-04-23 | 2026-03-31 |
| 审计意见(境内) | | | | 标准无保留意见 |